Navigation Links
Independent Studies Report on Possible Roles for Cylex's Immune Cell Function Assay in Monitoring of Heart and Lung Transplant Recipients
Date:4/9/2008

Six different studies will report on use of ImmuKnow assay in presentations at the annual meeting of the International Society for Heart and Lung

Transplantation

COLUMBIA, Md., April 9 /PRNewswire/ -- Since it was initially cleared as an in vitro diagnostic technique to detect cell-mediated immunity (CMI) in immune-suppressed adult patients, understanding of the possible applications of the Cylex(TM) ImmuKnow(R) assay (in clinical practice and in the clinical research setting) has been continuously expanding.

On Wednesday, April 9 through Saturday, April 12, at the annual meeting of the International Society for Heart and Lung Transplantation (ISHLT) Meeting in Boston, MA, an additional six presentations will report on studies of the use of the ImmuKnow assay in a variety of heart and lung transplant recipients:

Thursday, April 10

-- "Use of an immune monitoring assay to distinguish between fungal

colonization and fungal disease in lung transplant recipients"

(S. Husain, J. Pilewski, K. Spichty, et al.) -- oral presentation,

4:15 p.m. - 5:45 p.m. (Oral Session: Management of Emerging Infection

in Heart and Lung Transplantation)

-- "Immune cell function testing for the optimization of the therapeutic

drug monitoring in selected heart transplant patients, a case series"

(T. Ben Gal, V. Yaari, M. Israeli, et al.) -- poster presentation,

5:45 p.m. - 6:45 p.m. (General Posters: Poster Session II)

Friday, April 11

-- "Success of immune monitoring with ImmuKnow (Cylex) to assess

rejection/infectious risk in heart transplantation" (J. A. Kobashigawa,

K. K. Kiyosaki, J. K. Patel, et al.) - oral presentation, 10:45 a.m. --

12:45 p.m. (Oral Session: Can We Predict, Diagnose and Treat Cardiac

Rejection and Vasculopathy Before It's Too Late?)

-- "Assessment of the Cylex ImmuKnow cell function assay in pediatric

heart transplant patients" (J. W. Rossano, S. W. Denfield, E. O. Smith,

et al.) -- oral presentation, 10:45 a.m. - 12:45 p.m. (Oral Session:

The Long and the Short of Pediatric Immunosuppression and Immunology)

-- "Low Cylex immune response associated with increased infection in

pediatric heart transplants" (A. P. Barnes, S. M. Daneman, K. J.

Guleserian, et al.) -- poster presentation, 5:45 p.m. - 6:45 p.m.

(General Posters: Poster Session III)

-- "Monitoring for PTLD in children after lung transplantation"

(O. Elidemir, B. S. Kancheria, M. G. Schecter, et al.) -- poster

presentation, 5:45 p.m. - 6:45 p.m. (General Posters: Poster

Session III)

The various studies report on the clinical use of the ImmuKnow immune function assay in adult and in pediatric patients. The use of the ImmuKnow assay for identification of patients as described in some of these studies has not been cleared by the U.S. Food & Drug Administration (FDA). The company may use data from these or similar studies to support future FDA marketing applications.

About ImmuKnow(R)

ImmuKnow is an immune cell function assay that can detect cell-mediated immunity (CMI) in adult immunosuppressed patients by measuring the concentration of adenosine triphosphate (ATP) released from CD4 cells following cell stimulation.

The ImmuKnow test is a qualitative assay and does not directly quantify the level of immunosuppression. Results of ImmuKnow assays should be used in conjunction with clinical presentation, medical history, and other clinical indicators when assessing the immune status of any individual patient. The use of the ImmuKnow assay as described in these studies has not been cleared by the FDA. The company may use data from these or similar studies to support a future FDA marketing application for a similar indication.

ImmuKnow is a product of Cylex(TM), a privately held global life sciences company and the leader in the development and manufacture of research and in vitro diagnostic products intended to assist in the assessment of immune function.

About Cylex(TM) Inc.

Cylex(TM) is a privately held global life sciences company that is the leader in the development and manufacture of in vitro diagnostic products that are intended to illuminate immunity. ImmuKnow(R) is the in vitro diagnostic utilized to detect cell-mediated immunity (CMI) in an immunosuppressed population, and is increasingly being adopted at organ transplant centers throughout the US and abroad. The Company's patented technology provides an innovative platform allowing clinical researchers to simply and reproducibly measure CMI for the development of new diagnostics, biomarkers and companion assays. The Company is based in Columbia, MD.


'/>"/>
SOURCE Cylex Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Video: New Research Discovers Independent Brain Networks Control Human Walking
2. Facet Solutions AFRS(TM) Demonstrates Biomechanical Advantages Over Dynamic Stabilization in Independent Testing
3. Independent Clinical Results Confirm Up to a 7-Centimeter Reduction in Body Circumference Using UltraShape(TM) Non-Invasive Fat Reduction and Body Contouring System
4. Independent Physician Surveys Show if Approved, MF101 Could Become First-Line Treatment for Menopause Symptoms
5. Independent Data Safety Monitoring Board Recommends Continuation of Sangarts Pivotal Phase III Trials of Hemospan(R) Following Second Interim Review
6. Longevinex(R) Found to be Superior to Green Tea Molecule in Independent Human Study
7. Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine
8. Advanced Life Sciences to Present Data on Selected Cethromycin Therapeutic Studies at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
9. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
10. Schering-Plough Initiates Phase III Studies with Vicriviroc in Treatment- Experienced HIV Patients
11. Phase 2 Clinical Studies Initiated for a Novel Therapeutic Candidate Identified Through Pharmacopeia Collaboration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... -- The ALS Association, in partnership with ALS Finding a Cure, ... biomarker to track TDP43 aggregation. The successful team(s) with the ... investment. --> --> ... in the brain and the spinal cord. Eventually, people with ... which often leads to total paralysis and death within two ...
(Date:2/10/2016)... -- LexisNexis® Risk Solutions, a leading provider of data, ... LexisNexis Provider Performance Monitor , a clinical ... the quality and efficiency of provider networks through ... measuring provider performance through Provider Performance Monitor, payers ... improve the patient experience and reduce costs, as ...
(Date:2/10/2016)... SPRINGS, Florida , February 10, 2016 ... Pharmaceuticals, Inc. (NASDAQ: ADMS ) and Celldex Therapeutics, Inc. ... Inc. (NASDAQ: MDVN ), Adamas Pharmaceuticals, Inc. (NASDAQ: ... --> Today,s latest Orphan Drug Designations become vitally ... by the FDA to novel drugs and biologics which are ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... February 10, 2016 , ... Early this week, Team Iconic at J. Walter ... KITKAT as the first global confectionery brand sourced from 100% sustainable cocoa. , The ... of their product, through activities that focus on better farming, better lives and better ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... to expand dental health services to the developmentally disabled in the Coachella Valley. ... operations to a new facility at 71-949 Highway 111, Suite 100-B, in Rancho ...
(Date:2/10/2016)... ... February 10, 2016 , ... InDemand Interpreting , a ... partnered with Heart City Health Center to improve access to language ... City Health Center has provided the Elkhart community with access to high quality, ...
(Date:2/10/2016)... ... 10, 2016 , ... The Wickman Agency in Garland, TX ... local community. Pledging to select a new beneficiary every 60 days, the agency ... goal is to bring community awareness to important local causes by forming campaigns ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... his office is now offering a variety of comprehensive procedures for facial enhancement. ... lift, facial volume restoration, lip enhancement and nasal reshaping. , As a ...
Breaking Medicine News(10 mins):